cardiovascular diseases

News

Cytokinetics rockets on positive heart drug trial

Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.

News

BridgeBio rebounds on ATTR cardiomyopathy data

BridgeBio is getting ready to file for FDA approval of its acoramidis drug for transthyretin amyloidosis (ATTR) cardiomyopathy, armed with positive results in a phase 3 tr

News

Study prompts call for ‘30th birthday’ screening tests

Routine screening at 30 for three genetic conditions that predispose to cancer and cardiovascular disease could save health services money, according to a recently publish

News

AZ adds gene silencing tech to pipeline with Silence Therape...

AstraZeneca has announced a collaboration with UK biotech Silence Therapeutics to develop gene silencing drugs for cardiovascular, renal, metabolic and respiratory diseases.

Cytokinetics rockets on positive heart drug trial

BridgeBio rebounds on ATTR cardiomyopathy data

Study prompts call for ‘30th birthday’ screening tests

AZ adds gene silencing tech to pipeline with Silence Therape...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

cardiovascular diseases

Editor's Picks